There is an urgent caution being issued by experts regarding a potential symptom linked to drugs like Mounjaro and Ozempic.
Ozempic, an injectable medication primarily for individuals with type two diabetes to assist in managing blood sugar levels, has gained popularity among those seeking weight loss.
Semaglutide, the active ingredient in Ozempic, received approval from the US Food and Drug Administration (FDA) in 2017 for diabetic patients. However, some people are using it off-label for weight loss due to its appetite-suppressing effects.
Unlike Ozempic, Mounjaro has been FDA-approved for weight loss, in addition to its use in controlling blood sugar levels for diabetic patients.
The positive effects of these drugs are well-documented, but a recent study indicates a potential risk of vision loss for diabetic individuals using them.
Research conducted by the University of Toronto suggests that GLP-1 drugs, including Ozempic and Mounjaro, are associated with an increased risk of developing neovascular age-related macular degeneration (AMD).
Diabetic patients taking these medications were found to have more than double the likelihood of experiencing vision issues compared to non-diabetic users of Ozempic and Mounjaro.
AMD is described by the NHS as ‘a common condition that affects the middle part of your vision.’
According to Healthline, AMD is a leading cause of irreversible vision loss in individuals over the age of 50 in the United States.
Andrew Mihalache, MD(C), a co-author of the study, noted: “The dose-response effect we observed — where longer GLP-1 receptor agonist exposure was associated with higher risk — strengthens the argument that this association may reflect a true biological effect rather than being due to confounding factors.”
Reut Shor, MD, another author of the study, remarked: “This was definitely surprising, especially given the growing enthusiasm for GLP-1 receptor agonists for their cardiovascular and metabolic benefits. It really highlights the need for further investigation into their ocular safety profile.”
Despite this finding, the likelihood of developing vision loss from taking Ozempic and Mounjaro is still very low.
The study determined that the risk of AMD for those on a GLP-1 drug is 0.2 percent.
If you’re considering using a GLP-1 medication, it’s crucial to consult with a healthcare professional to determine if it’s suitable for you.